Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial.

Affiliation

Shi T(1), Zhu J(2), Feng Y(3), Tu D(4), Zhang Y(1), Zhang P(2), Jia H(5), Huang X(6), Cai Y(7), Yin S(1), Jiang R(1), Tian W(6), Gao W(2), Liu J(3), Yang H(6), Cheng X(6), Zang R(8).
Author information:
(1)Ovarian Cancer Program, Department of Gynaecologic Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
(2)Department of Gynaecologic Oncology, Cancer Hospital of the University of Chinese Academy of Sciences
(Zhejiang Cancer Hospital), Hangzhou, China.
(3)Department of Gynaecologic Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Sun Yat-sen University Cancer Centre, Guangzhou, China.
(4)Department of Mathematics and Statistics, Queen's University, Kingston, ON, Canada.
(5)Clinical Statistics Centre, Shanghai General Hospital, Shanghai, China.
(6)Department of Gynaecologic Oncology, Fudan University Cancer Hospital, Shanghai, China.
(7)Department of Obstetrics and Gynaecology, Zhongda Hospital Southeast University, Nanjing, China.
(8)Ovarian Cancer Program, Department of Gynaecologic Oncology, Zhongshan Hospital, Fudan University, Shanghai, China. Electronic address: [Email]

Abstract

Comment in Lancet Oncol. 2021 Apr;22(4):412-413. Lancet Oncol. 2021 Jun;22(6):e230. Lancet Oncol. 2021 Jun;22(6):e231. Lancet Oncol. 2021 Jun;22(6):e232. Lancet Oncol. 2021 Jun;22(6):e233.